한빛사논문
Kwangsik Nho 1,2,3,4,41, Shannon L. Risacher 1,3,41, Liana G. Apostolova 1,3,5,6, Paula J. Bice 1,3, Jared R. Brosch 3,5, Rachael Deardorff 3,5, Kelley Faber 6,7, Martin R. Farlow 3,5, Tatiana Foroud 3,6,7, Sujuan Gao 3,8, Thea Rosewood 1,2,3, Jun Pyo Kim 1,2,3, Kelly Nudelman 3,6,7, Meichen Yu 1,3, Paul Aisen 9, Reisa Sperling 10, Basavaraj Hooli 11, Sergey Shcherbinin 11, Diana Svaldi 11, Clifford R. Jack Jr. 12, William J. Jagust 13, Susan Landau 13, Aparna Vasanthakumar 14, Jeffrey F. Waring 14, Vincent Doré 15,16, Simon M. Laws 17, Colin L. Masters 18, Tenielle Porter 17, Christopher C. Rowe 16,18, Victor L. Villemagne 16,19, Logan Dumitrescu 20,21, Timothy J. Hohman 20,21, Julia B. Libby 20, Elizabeth Mormino 22, Rachel F. Buckley 10, Keith Johnson 10,23, Hyun-Sik Yang 10,24, Ronald C. Petersen 25, Vijay K. Ramanan 25, Nilüfer Ertekin-Taner 26,27, Prashanthi Vemuri 12, Ann D. Cohen 19, KangHsien Fan 28, M. Ilyas Kamboh 28, Oscar L. Lopez 19,29, David A. Bennett 30, Muhammad Ali 31, Tammie Benzinger 32, Carlos Cruchaga 31,33, Diana Hobbs 32, Philip L. De Jager 34, Masashi Fujita 34, Vaishnavi Jadhav 6,35, Bruce T. Lamb 3,6,35, Andy P. Tsai 22,35,36, Isabel Castanho 37,38, Jonathan Mill 37, Michael W. Weiner 39,40, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)*, the Department of Defense Alzheimer’s Disease Neuroimaging Initiative (DoD-ADNI)*, the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN)*, the Australian Imaging, Biomarker & Lifestyle Study (AIBL)*, Andrew J. Saykin 1,2,3,5,6,**
1Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA.
2Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, USA.
3Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, USA.
4Department of BioHealth Informatics, Indiana University, Indianapolis, USA.
5Department of Neurology,Indiana University School of Medicine, Indianapolis, USA.
6Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.
7National Centralized Repository for Alzheimer’s Disease and Related Dementias, Indiana University School of Medicine, Indianapolis, USA.
8Department of Biostatistics, Indiana University School of Medicine, Indianapolis, USA.
9Department of Neurology, Keck School of Medicine, University of Southern California, San Diego, USA.
10Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
11Eli Lilly and Company, Indianapolis, USA.
12Department of Radiology, Mayo Clinic, Rochester, USA.
13UC Berkeley Helen Wills Neuroscience Institute, University of California - Berkeley, Berkeley, USA.
14Genomics Research Center, AbbVie, North Chicago, USA.
15CSIRO Health and Biosecurity, Melbourne, Australia.
16Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia.
17Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia.
18Florey Institute of Neuroscience and Mental Health and The University of Melbourne, Parkville, Australia.
19Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA.
20Vanderbilt Memory & Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, USA.
21Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, USA.
22Department of Neurology & Neurological Sciences, Stanford University, Stanford, USA.
23Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
24Center for Alzheimer’s Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA.
25Department of Neurology, Mayo Clinic, Rochester, USA.
26Department of Neurology, Mayo Clinic, Jacksonville, USA.
27Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
28Department of Human Genetics, University of Pittsburgh, Pittsburgh, USA.
29Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, USA.
30Department of Neurological Sciences, Rush Medical College, Rush University, Chicago, USA.
31Department of Psychiatry, Washington University, St. Louis, USA.
32Department of Radiology, Washington University School of Medicine, St. Louis, USA.
33NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, USA.
34Center for Translational and Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, USA.
35Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, USA.
36Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, USA.
37Department for Clinical and Biomedical Sciences, University of Exeter Medical School, University of Exeter, Exeter, UK.
38Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
39Departments of Radiology, Medicine, and Psychiatry, University of California-San Francisco, San Francisco, USA.
40Department of Veterans Affairs Medical Center, San Francisco, USA.
41These authors contributed equally: Kwangsik Nho, Shannon L. Risacher.
*Lists of authors and their affiliations appear at the end of the paper.
**Corresponding author: correspondence to Andrew J. Saykin
Abstract
Determining the genetic architecture of Alzheimer's disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron emission tomography in 3046 participants from 12 independent studies. The CYP1B1-RMDN2 locus is associated with tau deposition. The most significant signal is at rs2113389, explaining 4.3% of the variation in cortical tau, while APOE4 rs429358 accounts for 3.6%. rs2113389 is associated with higher tau and faster cognitive decline. Additive effects, but no interactions, are observed between rs2113389 and diagnosis, APOE4, and amyloid beta positivity. CYP1B1 expression is upregulated in AD. rs2113389 is associated with higher CYP1B1 expression and methylation levels. Mouse model studies provide additional functional evidence for a relationship between CYP1B1 and tau deposition but not amyloid beta. These results provide insight into the genetic basis of cerebral tau deposition and support novel pathways for therapeutic development in AD.
논문정보
관련 링크
연구자 ID
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기